Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coverage With Evidence Development Won’t Go Far – Former CMS Staffer

This article was originally published in The Gray Sheet

Executive Summary

Comments by a former CMS staffer give further credence to growing suspicion that the agency's coverage-with-evidence-development (CED) policy is on the slow track

You may also be interested in...



AHRQ Works To Complete Patient Registry Reference Guide

HHS' Agency for Healthcare Research & Quality aims to complete a reference guide intended to facilitate wider use of patient registries by the end of the year

AHRQ Works To Complete Patient Registry Reference Guide

HHS' Agency for Healthcare Research & Quality aims to complete a reference guide intended to facilitate wider use of patient registries by the end of the year

Informed Consent Issues Proving Tricky In CMS Evidence-Development Policy

Issues surrounding informed consent appear to be complicating CMS' efforts to finalize a policy allowing it to require evidence collection as a condition of national Medicare coverage

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023387

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel